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Case  Study.  A  57-year-old  female  with  history  of 
myocardial  infarction  and  need  for  cardiac 
catheterization  with  stent  placement  requiring 
clopidogrel  for  many  years,  as  well  as  a  history  of 
hypertension requiring lisinopril, was evaluated by her 
gynecologist  for  ongoing  pelvic  pain.    She  had  no 
personal history of rheumatologic disorders, including 
systemic  sclerosis.    She  had  no  family  history  of 
cancers.    She  underwent  a  pelvic  ultrasound  which 
showed  bilateral  complex  ovarian  cysts.    She  was 
slated  for  a  laparoscopic  bilateral  salpingo-
oophorectomy (BSO), and clopidogrel was stopped 2 
weeks  prior  to  surgery.    Pre-operative  CA-125  level 
was normal, as was her complete blood count, hepatic, 
and renal function.  Upon laparoscopy, there was found 
to be enlargement of the right ovary with excrescences, 
grossly  suspicious  for  malignancy,  thus  requiring 
exploratory  laparotomy.    Frozen  section  of  the  right 
ovary  described  a  borderline  tumor,  and  a 
hysterectomy  was  then  performed  in  addition  to  the 
BSO.    Estimated  blood  loss  was  350  cc.    The  final 
pathology  confirmed  a  serous  Borderline  tumor 
without  microinvasion  or  evidence  of  invasive 
carcinoma in either ovary (Figure 1).  Postoperatively 
the  patient  was  given  thromboembolism  prophylaxis 
with  heparin  5000  U  subcutaneously  every  8  hours.  
She  developed  fevers  to  101  degrees  F  for  2  days 
without an obvious source of infection; blood and urine 
cultures  were  negative,  and  chest  x-ray  was 
unremarkable,  with  the  exception  of  atelectasis  .  
Empiric antibiotics however, were added. Neurologic 
examination  was  unremarkable  and  the  patient  was 
lucid  without  evidence  of  mental  status  changes.  
Creatinine  levels  rose  to  2.0  mg/dL,  thought  due  to 
hypovolemia,  and  intravenous  fluids  were  increased.  
A CBC showed decrease in the platelet count to 110 
K/ul (ref 142-424) on post-operative day (POD)#2, and 
to 63 K/ul on POD #3, when the patient was evaluated 
by a hematologist.  The hemoglobin (Hgb) level was  
8.1 g/dL (ref 12.2-16.2), prothrombin time (PT)  13.1 
seconds (ref 11.7-14.7 sec), fibrinogen 550 mg/dL (ref 
188-421  mg/dL),  lactate  dehydrogenase  (LDH)  2764 
U/L  (ref  313-618  U/L),  haptoglobin  level  <7  mg/dL 
(ref 42-312 mg/dL), and evaluation of the red cells by 
peripheral blood smear with 1-2 shistocytes per high-
powered  field  (HPF)  (Figure  2a).  D-dimer  levelMediterr J Hematol Infect Dis 2012; 4: Open Journal System
Figure 1. H+E stained sections of right ovary showing borderline serous tumor.  Courtesy of Dr. Sybil Irwin, Department of Pathology, 
Moses Taylor Hospital, Scranton, PA. 
(fibrin-degradation split products) was 2.68 ug/ml (ref 
0.0-0.42  ug/ml).    Cr  1.0  mg/dL  (ref  <1.2  mg/dL), 
which was improved from 2.0 mg/dL with the addition 
of  further  IV  fluids  on  POD#4.    The  patient  then 
developed  worsening  blood  pressure,  requiring 
antihypertensives including clonidine, and experienced 
chest pain with swelling in her legs; workup including 
CT  angiogram  and  an  ultrasound  of  the  lower 
extremities  with  Doppler  negative  for 
thromboembolism.    Heparin  was  stopped  and  an 
interim diagnosis of heparin-induced thrombocytopenia 
(HIT)  was  considered;  a  prophylactic  argatroban 
infusion  was  given  while  HIT  studies  were  pending 
and was continued empirically for 5 days.  On POD#4, 
platelets were 67 K/uL, Hgb 8.1 g/dL, LDH 2964 U/L, 
with  3-5  shistocytes  per  HPF  (Figure  2b),  with  D-
dimer (FDP) level 2.25 ug/ml She was neurologically 
intact and lucid.  The patient was placed on prednisone 
and  platelets  improved  to  83  K/uL  on  POD#5  with 
hemoglobin  7.7  g/dL  requiring  red  cell  transfusion, 
LDH  1694  U/L,  fibrinogen  556  mg/dL,  with  liver 
function testing normal.  HIT ELISA was negative as 
was  heparin-induced  platelet  aggregation  assay,  and 
there was no evidence LAC.  Factor VIII levels were 
followed, showing normal levels with no evidence of 
inhibitor, ristocetin cofactor activity was normal, and 
ADAMTS13 level . Creatinine level was then stable.  
The  patient  was  observed  on  prednisone  and  treated 
empirically for fevers.  On POD #6, the platelet count 
rose to 106 K/uL, hemoglobin to 7.9 g/dL, requiring 
additional  red  cell  transfusion,  LDH  stable  at  1610 
U/L, with examination of the peripheral blood smear 
showing  persistently  4-5  shistocytes  per  HPF,  and 
creatinine level of 1.2 mg/dL.  On POD#7, hgb level 
9.7 g/dL, platelets 177 K/ul, LDH 1618 U/L, Cr 1.2 
mg/dL, fibrinogen 301 mg/dL.  On POD#8, the platelet 
count rose to 222 K/ul, hemoglobin to 10.2 g/dL, LDH 
979  U/L,  peripheral  smear  with  3-4  shistocytes  per 
HPF, and stabilized for the rest of the hospitalization.  
The differential diagnosis  included microangiopathic 
hemolytic anemia (MAHA) associated with thrombotic 
thrombocytopenic  purpura  (TTP)/hemolytic-uremic 
syndrome  (HUS),  systemic  inflammatory  response 
syndrome  (SIRS),  antiphospholipid  antibody 
syndrome,  a  compensated  disseminated  intravascular 
coagulation  (DIC),  and  /or  hypertension-associatedMediterr J Hematol Infect Dis 2012; 4: Open Journal System
Figure 2. H+E stained peripheral blood smear showing shistocytes, 100X power.  (a) POD (post-operative day) #3, (b) POD#4. Courtesy of 
Dr. Sybil Irwin, Department of Pathology, Moses Taylor Hospital, Scranton, PA. 
MAHA.  In looking for specific trigger, we also asked 
the question as to whether MAHA has been triggered 
by ovarian tumors.  
Discussion.  Microangiopathic  hemolytic  anemia 
(MAHA) is historically described as a group of clinical 
disorders  characterized  by  fragmentation  of  the  red 
blood cells in the circulation and resultant intravascular 
hemolysis, occurring through fibrin deposits inside the 
lumens  of  arterioles  and  capillaries  or  through 
damaged  epithelium  and  vessel  walls.
1  Widespread 
microthrombi  occur  in  arterioles  and  capillaries  and 
can catalyze thrombocytopenia, especially during two 
prime disorders, thrombotic thrombocytopenic purpura 
(TTP) and hemolytic-uremic syndrome (HUS), which 
results  in  severe  MAHA,  for  which  a  major  clinical 
suspicion  must  always  be  ruled out. MAHA  may be 
observed  in  patients  who  experience  sepsis, 
disseminated  carcinomatosis,  disseminated 
intravascular  coagulation,  catastrophic 
antiphospholipid  antibody  syndrome  (APS),  organ 
transplantation, complications of pregnancy, malignant 
hypertension,  and  exposure  to  venoms,  toxins,  or 
antineoplastic  agents  such  a  mitomycin-C  or 
cyclosporine.
2-8  Clopidogrel  has  previously  been 
reported  to  cause  TTP  but  usually  this  has  been 
reported to occur within the first 2 weeks of initiation 
of the treatment.
9,10  Typically the classical  pentad of 
symptoms  associated  with  TTP  are  fevers,  central 
nervous  systems  changes,  hemolytic  anemia  with 
shistocytes on a peripheral blood smear and associated 
with  elevated  LDH,  renal  insufficiency,  and 
thrombocytopenia.  Clinically, only a triad of the latter 
three are sufficient  for  a clinical  diagnosis,  which is 
curable  with  aggressive  plasma  exchange  and 
pheresis.
11-14  Deficiency  of  ADAMTS13  von 
Willebrand  factor-cleaving  metalloprotease  has  been 
implicated in the pathogenesis of acute recurrent TTP, 
probably  resulting  from  the  combination  of  this 
deficiency  due  to  autosomal  recessive  trait  with 
decrease synthesis, intersecting with the mechanism of 
endothelial cell damage.
15 However, the clinical picture 
common to TTP and HUS may overlap with DIC or 
SIRS  in  a  patient  presenting  with  fevers  and 
thrombocytopenia.
16  In  addition,  catastrophic 
antiphospholipid  antibody  syndrome,  which  is  an 
immune reaction and “symptom-complex” difficult to 
distinguish from TTP-HUS, can also present with renal 
failure,  encephalopathy,  and  even  acute  respiratory 
distress syndrome, and can catalyze a hypercoagulable 
state.
17  Hence,  when  faced  with  these  clinical  signs, 
how does the consultant sort them out?  
We  report  another  confounding  trigger  to  the 
hemolytic  cascade  presented  here.    Tumor-induced 
MAHA is also associated with invasive and advanced 
malignancy,
18 and only one case report has linked this 
complication  with  a  benign  pelvic  tumor.
19
Overexpression  of  urokinase-type  plasminogen 
activator  in  ovarian  cancer  cells  may  lead  to 
hypercoagulability.
18  Of  paraneoplastic  syndromes 
associated  with  gynecologic  malignancies,  DIC  is  of 
the most common,
2,3,20-23 probably  caused by shearing 
of  RBCs  on  fibrin  strands  from  contact  with  tissue 
factor or with tumor cell emboli, a mechanism similar 
to that seen in mucin-releasing  GI malignancies.
24,25
Acute  promyelocytic  leukemia  also  causes  DIC  and 
MAHA  through  release  of  procoagulant,
26  a 
mechanism  also  reported  in  rhabdomyosarcoma  as  a 
specific  and  trackable  factor  VIII  antigen  homolog 
which can remit and relapse with disease progression,
27
as  can  increased  platelet  surface  sialytransferase 
activity  in  other  cancers.
28  Even  mechanical  heart 
valves  can cause MAHA  with raising  of FDP levels 
after shearing of RBCs.
29,30
How  the  clinician  should  proceed  analytically  is 
pivotal in deciding upon which intervention should be 
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made  in  a  timely  and  life-saving  fashion.    In  the 
assessment  of  anemia  and  thrombocytopenia  in  the 
postoperative or intensive care setting careful history is 
required related to prior hematologic disorders, onset 
of  disorder,  location  of  bleeding,  concurrent  illness, 
and  drug  exposure.    Pre-existing  organ  failure  may 
help the clinician to sort out these processes from acute 
MAHA  with  new  onset  organ  failure.
17  Physical 
examination  is  crucial  to  determining  likelihood  of 
acute infection and/or neurologic changes, as well as 
evidence  of  new  organ  failure  such  as  anuria  or 
oliguria,  to  evaluate  for  sites  of  bleeding  and/or 
bruising due to hemolysis or thrombocytopenia, and to 
evaluate for physical signs suspicious for thrombosis.  
Evaluation  of  the  coagulation  profile  including  PT, 
PTT,  fibrinogen,  D-dimer  (fibrin-split  products),  and 
lactate  dehydrogenase (LDH),  including  fractionation 
of  isoenzymes,    is  crucial  in  order  to  formulate  a 
differential  diagnosis.
17  Measurement  of  Factor  VIII 
levels  may  be  helpful  in  determining  extent  of 
consumption in DIC versus compensatory mechanisms 
activated  thus  elevating  the  levels  due  to  systemic 
inflammation; however, immediate quantitation of this 
level  may  not  be  readily  available  in  all  hospital 
laboratory  settings.    Visual  assessment  of  the 
peripheral  blood  smear  for  the  morphology  of  red 
blood cells to detect schistocytes or red cell fragments, 
presence of platelet clumping which may be related to 
chelating  without  EDTA  versus  lack  of  platelets 
produced.  Once acute thrombocytopenia is confirmed 
on the blood smear, HIT as a severe immune complex-
mediated  syndrome  caused  by  interaction  between 
heparin and heparin-induced platelet factor-4 should be 
considered, especially if the hallmarks of HIT are seen 
including  a  sudden decrease  in  the platelet  count  by 
50% of decrease from normal to less than 100,000 per 
ul is seen in the presence of heparin;
31 heparin therapy 
should be stopped immediately with an alternative to 
anticoagulation  initiated  such  as  direct  thrombin 
inhibitors  argatroban  or  lepirudin.      Red  blood  cell 
transfusions  may  be  indicated  if  blood  counts  drop 
severely below a level which causes clinical instability; 
but  platelet  transfusions  are  not  recommended  in 
literature  guidelines  until  a  firm  diagnosis  is 
established, as they are known to aggravate thrombosis 
in  HIT  as  well  as  TTP-HUS  by  adding  to  already 
activated platelet-thrombin complexes,  and  are of no 
proven  benefit  in immune  thrombocytopenic  purpura 
unless there is evidence of acute bleeding.
32
Conclusion. We present here a case of a 57-year-old 
woman  previously  on  clopidogrel,  who  experienced 
MAHA after surgery for an ovarian mass which was 
deemed  pathologically  as  a  borderline  serous  tumor.  
Her  baseline  CBC,  liver  and  renal  functions  were 
normal.    However,  post-operatively  she  experience 
fevers, renal insufficiency, hypertension, and MAHA 
with  shistocytes  and  elevated  LDH  as  well  as 
thrombocytopenia, all suspicious for TTP, but further 
sorting of clinical information led to other differential 
diagnoses,  including fever from atelectasis or SIRS, 
with  elevated  fibrinogen  as  in  acute  phase  reaction; 
renal  insufficiency  from  hypovolemia,  as  this 
responded  to  fluids;  the  possibility  of  malignant 
hypertension; and the possibility of DIC triggered from 
the  release  of  intracellular  contents  from  a  necrotic 
ovarian tumor.   
Multiple triggers of the coagulation system can lead 
to  a  common  pathway  of  hemostatic  failure  that 
incorporates  the  systemic  inflammatory  response, 
leading to multiple organ failure.  The specific criteria 
seen in DIC, TTP, HIT, and catastrophic APS seem to 
overlap.  The key maneuver is determining the trigger 
(i.e.,  infection  or  medication),  and  tracking  possible 
and available hemostatic markers through the clinical 
course,  such  as  plasma  thrombomodulin  (TM), 
antithrombin, protein C levels, which are elevated (the 
former) or markedly reduced (the latter), especially in 
patients  with  DIC  and  TTP.
33  On  initial presentation 
there  is  an  often  an  overlapping  of  differential 
diagnoses and possible interventions.  Some common 
characteristics  may  include  the  activation  of  the 
coagulation system from direct contact of tumor cells 
with  tissue  factor,  vis  a  vis,  with  elevated  and 
qualitative Factor VIII, MAHA from fibrin stranding, 
or  the  presence  of  antiphospholipid  antibodies.  The 
difficult task is embarking on the correct and logical 
hematologic  intervention(s),  whether  anticoagulation, 
steroids,  transfusion,  or  aggressive  plasma  exchange; 
while  life-saving  in  HUS/TTP,  the  latter  may  pose 
cardiovascular risk in some patients significant enough 
to  consider  the  short-term  risk  versus  benefit  ratio.  
This case demonstrated a scenario of multiple possible 
triggers  for  MAHA,  all  of  which  may  overlap 
clinically.    Here,  markers  including  elevated  factor 
VIII levels suggested inflammatory response over other 
consumptive processes; however, as these entities were 
further  being  investigated  for  their  confirmation,  the 
patient  was  initially  treated  with  a  combination  of 
alternative anticoagulation, a trial of steroids, empiric 
antibiotics, and observed for other signs of multiorgan 
failure.  Clinical judgment must then prevail in staving 
off  a  potentially  tenuous  situation,  guarding  toward 
possible  clinical  compromise  requiring  aggressive 
intervention,  versus  one  that  may  be  treated 
supportively based upon the underlying disorder. 
In  Figure  3,  we  summarize  and  propose  a 
chronologic  and  strategic  approach  for  the  clinician 
who  is  faced  with  this  dilemma  of  post-operative 
MAHA with thrombocytopenia and renal insufficiency  Mediterr J Hematol Infect Dis 2012; 4: Open Journal System
Figure 3. Flow diagram of proposed analytical decision-making in cases of hemostatic failure, which stem from multiple possibilities in a 
differential diagnosis;  while these converge at a common pathway marked by overt hemostatic failure, pursuit of a final diagnosis guides 
specific  intervention.    Abbreviations:  Abs=antibodies;  APL=  antiphospholipid  antibody  syndrome;  DIC=disseminated  intravascular 
coagulation;  FDP=fibrin  degradation  products;  MAHA=microangiopathic  hemolytic  anemia;  HIT  =  heparin-induced  thrombocytopenia; 
plt=platelet; TTP= thrombotic thrombocytopenic purpura. 
with a large differential diagnosis including TTP, HIT, 
APL, and DIC.  (a) Careful history must be taken with 
attention the onset of change in the CBC, induction of 
hemolysis, and consumption of platelets, concomitant 
with  drug  exposure,  and  put  into  clinical  context; 
abrupt onset may suggest acute change, and a list of 
drugs  may  point  toward  more  specific  inciting 
mechanisms.  (b) Physical examination with attention 
to  hematologic  manifestations  such  as  purpura, 
thrombosis,  and  hemorrhage  may  help  to  distinguish 
the severity of the condition and would guide toward 
the absolute need for anticoagulation.  (c) Immediate 
laboratory  investigation  of  coagulation  profile  to 
distinguish  DIC  from    other  hemostatic  disorders, 
including  APL  with  the  elevation  of  PTT  alone  and 
presence  of  associated  antibodies,  or  a  more  normal 
coagulation profile in which platelet consumption may 
preside.  (d)  Visual  assessment  of  blood  cell 
morphology  for  red  cell  fragmentation  or  platelet 
aggregation  is  essential.    Further  distillation  of  the 
pathogenesis of hemostatic failure is illustrated as the 
final ability of platelets to interact  with larger  blood 
vessels, and to form a clot with sustainable integrity.  
The  above  described  “markers”  of  impending 
hemostatic failure can help to determine which entity 
in the differential diagnosis to more fully pursue, and 
which  specific  intervention  to  follow,  including 
plasmapheresis  for  TTP;  anticoagulation  for  APL  or 
even DIC (or its alternative for HIT);  or treatment of 
the  underlying  cause  with  support  from  indicated 
transfusions  for  DIC.  In  this  particular  situation,  a 
SIRS-like phenomenon was felt to prevail, and did not 
require a  more  intense intervention,  but  a  successful 
supportive approach. 
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